MoonLake Immunotherapeutics (NASDAQ:MLTX) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in a research report released on Friday,Benzinga reports. HC Wainwright currently has a $100.00 price target on the stock.

MLTX has been the subject of a number of other reports. Wedbush restated an “outperform” rating and issued a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $62.00 price target on shares of MoonLake Immunotherapeutics in a research note on Thursday, September 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $81.43.

MoonLake Immunotherapeutics Trading Down 3.9 %

MoonLake Immunotherapeutics stock opened at $46.31 on Friday. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $64.98. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of -35.90 and a beta of 1.31. The business’s fifty day simple moving average is $52.17 and its two-hundred day simple moving average is $48.91.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same quarter in the prior year, the firm earned ($0.18) EPS. On average, equities research analysts predict that MoonLake Immunotherapeutics will post -1.75 EPS for the current year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP raised its stake in shares of MoonLake Immunotherapeutics by 1.9% in the third quarter. GSA Capital Partners LLP now owns 22,127 shares of the company’s stock worth $1,116,000 after buying an additional 403 shares during the period. US Bancorp DE purchased a new stake in MoonLake Immunotherapeutics in the 3rd quarter worth approximately $44,000. HighVista Strategies LLC raised its stake in MoonLake Immunotherapeutics by 3.1% during the 3rd quarter. HighVista Strategies LLC now owns 43,541 shares of the company’s stock worth $2,195,000 after acquiring an additional 1,292 shares during the period. Parkman Healthcare Partners LLC lifted its holdings in MoonLake Immunotherapeutics by 1.6% during the third quarter. Parkman Healthcare Partners LLC now owns 102,813 shares of the company’s stock valued at $5,184,000 after purchasing an additional 1,589 shares in the last quarter. Finally, Quarry LP boosted its position in shares of MoonLake Immunotherapeutics by 172.7% in the second quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $132,000 after purchasing an additional 1,900 shares during the period. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.